{
    "root": "0bdf77ae-3639-49c1-b7c7-533f9d073084",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "posaconazole"
    },
    "value": "20240925",
    "ingredients": [
        {
            "name": "POSACONAZOLE",
            "code": "6TK1G07BHZ"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE ACETATE SUCCINATE, UNSPECIFIED",
            "code": "A7ZHS2RJ34"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLYETHYLENE GLYCOL 4000",
            "code": "4R4HFI6D95"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "posaconazole azole antifungal indicated follows : posaconazole indicated prophylaxis invasive aspergillus candida infections patients high risk developing infections due severely immunocompromised , hematopoietic stem cell transplant ( hsct ) recipients graft-versus-host disease ( gvhd ) hematologic malignancies prolonged neutropenia chemotherapy follows : ( 1.2 ) posaconazole delayed-release tablets : adults pediatric patients 2 years age older weigh greater 40 kg",
    "contraindications": "noxafil \u00ae oral suspension substitutable posaconazole delayed-release tablets noxafil \u00ae powdermix delayed-release oral suspension due differences dosing formulation . therefore , follow recommendations formulations . ( 2.1 , 2.2 , 2.3 ) administer posaconazole delayed-release tablets without food . ( 2.1 ) table 1 : recommended adult patients indication form , dose , duration therapy prophylaxis invasive aspergillus candida infections delayed-release tablets : loading dose : 300 mg ( three 100 mg delayed-release tablets ) twice day first day . maintenance dose : 300 mg ( three 100 mg delayed-release tablets ) day , starting second day . duration therapy based recovery neutropenia immunosuppression . ( 2.2 , 2.3 ) pediatric patients , full prescribing information dosing recommendations posaconazole delayed-release tablets ( 1.2 , 2.1 , 2.3 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "known hypersensitivity posaconazole azole antifungal agents . ( 4.1 ) coadministration posaconazole following drugs contraindicated ; posaconazole increases concentrations toxicities : sirolimus ( 4.2 , 5.1 , 7.1 ) cyp3a4 substrates ( pimozide , quinidine ) : result qtc interval prolongation cases torsades de pointes ( tdp ) ( 4.3 , 5.2 , 7.2 ) hmg-coa reductase inhibitors primarily metabolized cyp3a4 ( 4.4 , 7.3 ) ergot alkaloids ( 4.5 , 7.4 ) venetoclax : patients chronic lymphocytic leukemia ( cll ) small lymphocytic lymphoma ( sll ) initiation ramp-up phase ( 4.6 , 5.11 , 7.16 )",
    "indications_original": "Posaconazole\u00a0is an azole antifungal indicated as follows: Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) o Posaconazole delayed-release tablets: adults and pediatric patients\u00a02 years of age and older who weigh greater than 40 kg",
    "contraindications_original": "Noxafil \u00ae oral suspension is not substitutable with posaconazole delayed-release tablets or Noxafil \u00ae PowderMix for delayed-release oral suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations. ( 2.1 , 2.2 , 2.3 ) Administer posaconazole delayed-release tablets with or without food. ( 2.1 ) Table 1: Recommended Dosage in Adult Patients Indication Dosage Form, Dose, and Duration of Therapy Prophylaxis of invasive Aspergillus and Candida infections Delayed-Release Tablets: Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a day on the first day. Maintenance dose: 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. Duration of therapy is based on recovery from neutropenia or immunosuppression. ( 2.2 , 2.3 ) For pediatric patients, see the Full Prescribing Information for dosing recommendations for posaconazole delayed-release tablets ( 1.2 , 2.1 , 2.3 )",
    "adverseReactions_original": "Known hypersensitivity to posaconazole or other azole antifungal agents. ( 4.1 ) Coadministration of posaconazole with the following drugs is contraindicated; posaconazole increases concentrations and toxicities of: Sirolimus ( 4.2 , 5.1 , 7.1 ) CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP) ( 4.3 , 5.2 , 7.2 ) HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.3 ) Ergot alkaloids ( 4.5 , 7.4 ) Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase ( 4.6 , 5.11 , 7.16 )"
}